Suppr超能文献

帕金森病非运动症状治疗的研究进展——基于循证医学的评价

Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review.

机构信息

Department of Neurology, Medical University Innsbruck, Innsbruck, Austria.

Institute of Psychiatry, Psychology & Neuroscience at King's College and Parkinson Foundation International Centre of Excellence at King's College Hospital, Denmark Hill, London, United Kingdom.

出版信息

Mov Disord. 2019 Feb;34(2):180-198. doi: 10.1002/mds.27602. Epub 2019 Jan 17.

Abstract

OBJECTIVE

To update evidence-based medicine recommendations for treating nonmotor symptoms in Parkinson's disease (PD).

BACKGROUND

The International Parkinson and Movement Disorder Society Evidence-Based Medicine Committee's recommendations for treatments of PD were first published in 2002, updated in 2011, and now updated again through December 31, 2016.

METHODS

Level I studies testing pharmacological, surgical, or nonpharmacological interventions for the treatment of nonmotor symptoms in PD were reviewed. Criteria for inclusion and quality scoring were as previously reported. The disorders covered were a range of neuropsychiatric symptoms, autonomic dysfunction, disorders of sleep and wakefulness, pain, fatigue, impaired olfaction, and ophthalmologic dysfunction. Clinical efficacy, implications for clinical practice, and safety conclusions are reported.

RESULTS

A total of 37 new studies qualified for review. There were no randomized controlled trials that met inclusion criteria for the treatment of anxiety disorders, rapid eye movement sleep behavior disorder, excessive sweating, impaired olfaction, or ophthalmologic dysfunction. We identified clinically useful or possibly useful interventions for the treatment of depression, apathy, impulse control and related disorders, dementia, psychosis, insomnia, daytime sleepiness, drooling, orthostatic hypotension, gastrointestinal dysfunction, urinary dysfunction, erectile dysfunction, fatigue, and pain. There were no clinically useful interventions identified to treat non-dementia-level cognitive impairment.

CONCLUSIONS

The evidence base for treating a range of nonmotor symptoms in PD has grown substantially in recent years. However, treatment options overall remain limited given the high prevalence and adverse impact of these disorders, so the development and testing of new treatments for nonmotor symptoms in PD remains a top priority. © 2019 International Parkinson and Movement Disorder Society.

摘要

目的

更新针对帕金森病(PD)非运动症状的循证医学推荐。

背景

国际帕金森病和运动障碍协会循证医学委员会针对 PD 的治疗建议于 2002 年首次发布,2011 年进行了更新,现在又更新至 2016 年 12 月 31 日。

方法

我们回顾了针对 PD 非运动症状的治疗进行药理学、手术或非药理学干预的 I 级研究。纳入标准和质量评分标准与之前报道的相同。涵盖的疾病包括一系列神经精神症状、自主神经功能障碍、睡眠和觉醒障碍、疼痛、疲劳、嗅觉障碍和眼科功能障碍。报告了临床疗效、对临床实践的影响以及安全性结论。

结果

共有 37 项新研究符合审查条件。没有随机对照试验符合治疗焦虑障碍、快速眼动睡眠行为障碍、过度出汗、嗅觉障碍或眼科功能障碍的纳入标准。我们确定了对治疗抑郁症、淡漠、冲动控制和相关障碍、痴呆、精神病、失眠、白天嗜睡、流涎、体位性低血压、胃肠道功能障碍、尿功能障碍、勃起功能障碍、疲劳和疼痛有用或可能有用的干预措施。针对非痴呆水平认知障碍,没有发现有用的干预措施。

结论

近年来,针对 PD 一系列非运动症状的治疗证据基础有了很大的增长。然而,鉴于这些疾病的高患病率和不良影响,总体治疗选择仍然有限,因此开发和测试 PD 非运动症状的新治疗方法仍然是当务之急。

相似文献

1
Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review.
Mov Disord. 2019 Feb;34(2):180-198. doi: 10.1002/mds.27602. Epub 2019 Jan 17.
4
7
Nonmotor symptoms in nursing home residents with Parkinson's disease: prevalence and effect on quality of life.
J Am Geriatr Soc. 2013 Oct;61(10):1714-21. doi: 10.1111/jgs.12458. Epub 2013 Oct 1.
8
Nonmotor disturbances in Parkinson's disease.
Neurodegener Dis. 2011;8(3):95-108. doi: 10.1159/000316613. Epub 2010 Dec 23.
9
New clinical trials for nonmotor manifestations of Parkinson's disease.
Mov Disord. 2015 Sep 15;30(11):1490-504. doi: 10.1002/mds.26415.
10
Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease.
Mov Disord. 2015 Jun;30(7):919-27. doi: 10.1002/mds.26170. Epub 2015 Mar 4.

引用本文的文献

1
Factors Influencing Pain Management Practices in People With Parkinson's Disease: A Qualitative Descriptive Study.
Parkinsons Dis. 2025 Aug 1;2025:1231126. doi: 10.1155/padi/1231126. eCollection 2025.
3
Management of Gastrointestinal Symptoms in Parkinson's Disease.
J Cent Nerv Syst Dis. 2025 Aug 13;17:11795735251370014. doi: 10.1177/11795735251370014. eCollection 2025.
4
Pharmacotherapy in Early Parkinson's Disease: A Pragmatic Approach.
Ann Indian Acad Neurol. 2025 Jul 1;28(4):512-518. doi: 10.4103/aian.aian_676_25. Epub 2025 Aug 14.
5
Neuropsychiatric disorders in Parkinson's disease.
Ther Adv Neurol Disord. 2025 Jul 28;18:17562864251356062. doi: 10.1177/17562864251356062. eCollection 2025.
10
Outpatient interface challenges for drug safety in Parkinson's disease patients: a questionnaire based cross-sectional study.
Front Neurol. 2025 Jun 19;16:1563636. doi: 10.3389/fneur.2025.1563636. eCollection 2025.

本文引用的文献

1
Elastic Abdominal Binders Attenuate Orthostatic Hypotension in Parkinson's Disease.
Mov Disord Clin Pract. 2015 Nov 27;3(2):156-160. doi: 10.1002/mdc3.12270. eCollection 2016 Mar-Apr.
2
Sildenafil in the Treatment of Erectile Dysfunction in Parkinson's Disease.
Mov Disord Clin Pract. 2016 Nov 20;4(3):412-415. doi: 10.1002/mdc3.12456. eCollection 2017 May-Jun.
3
Mortality in patients with Parkinson disease psychosis receiving pimavanserin and quetiapine.
Neurology. 2018 Oct 23;91(17):797-799. doi: 10.1212/WNL.0000000000006396. Epub 2018 Sep 26.
4
Olfactory Dysfunction in Neurodegenerative Diseases.
Curr Allergy Asthma Rep. 2018 Jun 15;18(8):42. doi: 10.1007/s11882-018-0796-4.
5
Cardiovascular Safety of Psychiatric Agents: A Cautionary Tale.
Angiology. 2019 Feb;70(2):103-129. doi: 10.1177/0003319718780145. Epub 2018 Jun 6.
6
Evaluating the risk of QTc prolongation associated with antidepressant use in older adults: a review of the evidence.
Ther Adv Drug Saf. 2018 Jun;9(6):297-308. doi: 10.1177/2042098618772979. Epub 2018 May 4.
7
Non-motor Parkinson disease: new concepts and personalised management.
Med J Aust. 2018 May 21;208(9):404-409. doi: 10.5694/mja17.00993.
8
Pimavanserin evaluated by the FDA.
Lancet. 2018 May 5;391(10132):1762. doi: 10.1016/S0140-6736(18)31002-X.
10
Treating refractory depression in Parkinson's disease: a meta-analysis of transcranial magnetic stimulation.
Transl Neurodegener. 2018 Mar 22;7:8. doi: 10.1186/s40035-018-0113-0. eCollection 2018.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验